Drug Profile
Research programme: I-kappa B kinase/NF-kappa B inhibitors - Novo Nordisk
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Novo Nordisk
- Class
- Mechanism of Action I-kappa B kinase inhibitors; NF-kappa B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Diabetes-mellitus(Prevention) in Denmark
- 02 Oct 2009 Preclinical trials in Diabetes mellitus in Denmark (unspecified route)